Safety of metformin in the treatment of elderly type 2 diabetes mellitus
- VernacularTitle:二甲双胍在老年2型糖尿病患者应用的安全性评估
- Author:
Hui TIAN
;
Chunlin LI
;
Guang YANG
;
Yinzhang WANG
;
Wenyi ZONG
;
Yinghong SHAO
;
Shuangtong YAN
;
Jian LI
;
Junhua HUANG
;
Yanping GONG
;
Minyan LIU
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Mefformin;
Aged;
Drug safety
- From:
Chinese Journal of Internal Medicine
2008;47(11):914-918
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety of mefformin in the treatment of elderly type 2 diabetes mellitus(T2DM). Methods Two hundred and forty-three cases of elderly T2DM hospitalized from Jan.1996 to Dec. 2006 were reviewed; the changes of fasting blood glucose(FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), liver and renal function and blood lactic acid were evaluate before and after treatment. Results The mean time of treatment with mefformin was (6.6±3.9) years (3 months-21 years)in these 243 cases. The levels of FBG, PBG and HbAlc significantly reduced after treatment with mefformin only in 43 cases (17.7%), mefformin combined with other oral hypoglycemic drugs in 124 cases (51.0%) and mefformin combined with insulin in 76 cases (31.3%). There was only 18.1% of the cases with normal range ( > 80 ml/min) of creatinine clearance rate (Ccr), and 25.8% of the cases with Ccr≤50 ml/min. The liver and renal function as well as the blood lactic acid had no significant change after treatment no matter in total cases or in different groups separated by Ccr.Conclusions Mefformin is safety in the treatment of elderly T2DM patients. Ageing is not the contraindication of mefformin. To the patients with high risk, we should monitoring the level of blood lactic acid.
